Emiltatug ledadotin

Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC) . Emiltatug ledadotin consists of a tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918), a linker-payload system built on the novel Dolasynthen (DS) ADC platform (HY-177541), and achieves site-specific conjugation via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used for the study of B7-H4-overexpressing advanced solid tumors, particularly breast, ovarian, and endometrial cancers[1].

Product Specifications

CAS Number

[2855974-40-0]

Product Name Alternative

Emi-Le; XMT-1660

UNSPSC

12352005

Target

Antibody-Drug Conjugates (ADCs)

Related Pathways

Antibody-drug Conjugate/ADC Related

Field of Research

Cancer

Smiles

[Emiltatugledadotin]

References & Citations

[1]Toader D, et al. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Mol Cancer Ther. 2023 Sep 5;22 (9) :999-1012.